Emmaus Life Sciences Files 8-K on Director/Officer Changes

Ticker: EMMA · Form: 8-K · Filed: Jul 17, 2024 · CIK: 822370

Emmaus Life Sciences, INC. 8-K Filing Summary
FieldDetail
CompanyEmmaus Life Sciences, INC. (EMMA)
Form Type8-K
Filed DateJul 17, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: director-changes, officer-changes, corporate-governance, financial-statements

Related Tickers: EMMA

TL;DR

Emmaus Life Sciences (EMMA) filed an 8-K detailing director/officer changes and financial exhibits.

AI Summary

Emmaus Life Sciences, Inc. filed an 8-K on July 17, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported as July 15, 2024.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in board and officer composition can indicate internal shifts that may impact future performance.

Key Players & Entities

FAQ

What specific changes were made regarding directors and officers?

The 8-K filing indicates the departure of directors, election of new directors, and the appointment of certain officers, along with details on compensatory arrangements.

What is the earliest date for events reported in this 8-K?

The earliest event reported in this 8-K filing is July 15, 2024.

What is the company's state of incorporation?

Emmaus Life Sciences, Inc. is incorporated in Delaware.

What is the SEC file number for this filing?

The SEC file number for this 8-K filing is 001-35527.

Besides director and officer changes, what other information is included?

The filing also includes financial statements and exhibits.

Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-07-17 17:28:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 17, 2024 EMMAUS LIFE SCIENCES, INC. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing